Reata Pharmaceuticals Down 30% After Hours on FDA Advisory Panel Vote
December 08 2021 - 07:25PM
Dow Jones News
By Josh Beckerman
Reata Pharmaceuticals Inc. shares were recently down 30% to $38
after hours after the company received a negative opinion from a
Food and Drug Administration advisory committee for its new drug
application for bardoxolone methyl.
Reata shares were halted all day Wednesday.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
December 08, 2021 19:10 ET (00:10 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Dec 2021 to Jan 2022
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Jan 2021 to Jan 2022
